Changing of hepatitis B virus markers in patients with bone marrow transplantation.
The hepatitis B virus (HBV) infection and its resulting hepatic abnormalities are very high in prevalence among the Taiwan population. They also seem to compose a major problem to patients subjected to bone marrow transplantation (BMT) due to intensive chemoradiotherapy. In this study, the sera of 42 patients were investigated before and after BMT to detect the presence of HBV markers and to test their liver function (LF). Being followed-up for 3-12 months after BMT, 12 out of 27 were found to have altered HBV markers according to the classification of the following: seroconversion of HBsAg, clearance of HBsAb, appearance of HBeAg, clearance of HBeAb, and acute hepatitis. Thirty-seven out of 42 patients (88.1%) were found in routine LF test to develop one or more abnormality; however, 90% of them turned normal within one year after BMT. Only one patient died of complications associated with fulminant hepatitis. In conclusion, the previous hepatic damage from HBV infection appears unlikely to increase the risk of posttransplant morbidity and mortality.
Chen
P M
PM
Department of Internal Medicine and Nuclear Medicine, Veterans General Hospital, Taipei, Taiwan, Republic of China.
Fan
S
S
Liu
C J
CJ
Hsieh
R K
RK
Liu
J H
JH
Chuang
M W
MW
Liu
R S
RS
Tzeng
C H
CH
D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006510:Hepatitis B Antibodies / Q000378:metabolism*; D006511:Hepatitis B Antigens / Q000096:biosynthesis / Q000276:immunology*; D006801:Humans; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged
D006510:Hepatitis B Antibodies; D006511:Hepatitis B Antigens